Looking back at the November 2020 installment of Urology Times’ Around the Practice, a virtual, monthly live case event focused on genitourinary cancers, Raoul S. Concepcion, MD, FACS, offers an update on clinical implications from two prostate cancer cases.
In November 2020, Urology Times hosted its monthly virtual case event, designed to provide insight from urology, medical oncology, and radiation oncology providers on 3 cases: metastatic castrate-sensitive prostate cancer, non-metastatic castrate-resistant prostate cancer, and de novo metastatic renal cell carcinoma.
Moderator, Raoul S. Concepcion, MD, FACS, joined Urology Times to offer an update on these cases, with potential clinical implications for the future.
To watch the full discussion on demand, visit urologytimes.com.
Phase 1B trial to evaluate relugolix and enzalutamide in high-risk prostate cancer
July 24th 2024"Going forward after this study, we hope to be able to expand and potentially look at patients undergoing either surgery or radiation therapy, and really try to determine the potential benefit," says Kelly L. Stratton, MD, FACS.